Lymphomas
Select Clinical Trial
Protocol Number: SWOG 1826 Hodgkin Lymphoma
Protocol Title: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 18 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.
Eligibility: Patient population age 18 years or older with newly diagnosed advanced stage Classical Hodgkin Lymphoma.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: Alliance A041702 Chronic Lymphocytic Leukemia (CLL)
Protocol Title: Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients.
Eligibility: Patient population 70 years or greater that have received no treatment for confirmed Chronic Lymphocytic Leukemia (CLL).
Contact Information: (910) 715-2200